BBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BridgeBio Pharma Inc (BBIO) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong growth prospects, positive analyst sentiment, and upcoming catalysts outweigh the short-term price fluctuations.
The technical indicators suggest a generally bullish trend. The MACD is positive and contracting, the RSI is neutral at 59.08, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 71.474, with resistance at 74.57 and support at 68.378.
Analysts have raised price targets significantly, with targets ranging from $81 to $125, citing strong growth in Attruby sales and promising drug pipeline developments.
Recent submission of a New Drug Application for BBP-418 and positive Phase 3 results for Acoramidis indicate strong long-term growth potential.
The company's gross margin increased significantly to 94.74%, showcasing operational efficiency.
The stock has seen a recent decline in price (-1.75% regular market, -0.29% post-market), which could deter short-term traders.
Net income and EPS have dropped YoY, indicating profitability challenges in the short term.
In Q4 2025, revenue increased by 2521.18% YoY to $154.18M, driven by strong product sales. However, net income dropped by -27.24% YoY to -$192.86M, and EPS fell by -28.57% YoY to -1. Gross margin improved significantly to 94.74%, up 46.72% YoY, reflecting strong operational performance.
Analysts are overwhelmingly positive on BBIO, with multiple firms raising price targets and maintaining Outperform or Buy ratings. Key drivers include strong Attruby sales, promising drug pipeline developments, and potential upside from litigation outcomes.
